INTRODUCTION {#s1}
============

65 millions of people were affected by epilepsy in the world according to International League Against Epilepsy (ILAE) \[[@R1]\], and approximately 36% of epilepsy patients were drug-resistant \[[@R2]\]. Varieties of genes encoding channels, receptors, transporters, synaptic transmission, etc. have been associated with different types of epilepsy, among which, some were associated with refractory epilepsy \[[@R3], [@R4], [@R5], [@R6]\]. Many environmental factors, such as economic situation, diet, trauma, stroke, etc. were also associated with epilepsy or seizure \[[@R7], [@R8], [@R9], [@R10]\].

Epigenetic modifications, including DNA methylation, histone modification and aberrant microRNA expression, can affect genomic reprogramming, tissue-specific gene expression and global gene silencing without affecting DNA sequence itself \[[@R11], [@R12]\]. The most common form of DNA methylation occurs at the 5'carbon of cytosine in CpG dinucleotides which often locates in CpG islands within the promoters \[[@R13]\]. More recently, DNA methylation is raised as one of the main epigenetic mechanisms in epilepsy \[[@R14]\]. Previous genome-wide DNA methylation profiling in epileptic animal models presented altered DNA methylation in promoters of genes, and identified many genes that were associated with epilepsy \[[@R15]\].

DNA methylation in promoter may decrease gene expression, for example, increased methylation of reelin promoter resulted in the decrease of reelin expression in epilepsy model \[[@R16]\]. Katja Kobow and colleagues found a genome-wide distinctive DNA methylation pattern in rat models of pilocarpine-induced epilepsy in addition to an inverse relationship between gene expression and DNA methylation in promoter, exon and intron \[[@R17]\]. Meanwhile, ketogenic diet could attenuate seizure progression via ameliorating DNA methylation \[[@R17]\]. Selective changes in genome-wide DNA methylation and increased DNA-methyltransferase were also discovered in patients with temporal lobe epilepsy (TLE) \[[@R18], [@R19]\]. However, the profiling of genome-wide DNA methylation and gene expression in patients with refractory epilepsy remains unclear.

In this study, methylated DNA immunoprecipitation linked with sequencing (MeDIP-Seq) and mRNA sequencing (mRNA-Seq) were used to analyze the pattern of genome-wide DNA methylation and gene expression, as well as the relationship between DNA methylation and gene expression. Our findings identified a new distribution pattern of DNA methylation and gene expression in refractory epilepsy patients. Most of the differentially methylated genes (DMG) were methylated in gene element of coding sequences (CDS) and introns. More importantly, some new refractory epilepsy-related genes that have not been documented previously were found in this study.

RESULTS {#s2}
=======

Demographic and clinical characteristics of subjects {#s2_1}
----------------------------------------------------

The mean age (mean±SD) of the 10 epileptic samples (5 male/5 female) was 17.10±5.84, and the age of epilepsy onset was 6.49±6.16. The mean age of the 10 controls (7 male/3 female) was 39.00±17.40. The detailed data of demographic and clinical characteristics of epileptic samples were presented in Table [1](#T1){ref-type="table"} & [Supplementary Table S1](#SD1){ref-type="supplementary-material"}.

###### Clinical characteristics of patients and controls

  Characteristics                   Patients     Controls
  --------------------------------- ------------ -------------
  Age (year)                        17.10±5.84   39.00±17.40
  Age of onset (year)               6.49±6.16    N/A
  Sex (male/female)                 5/5          7/3
  Frequency of seizures per month                N/A
   \<10                             5            
   10∼100                           1            
   \>100                            4            
  Pattern of seizures                            N/A
   GS                               4            
   GTCS+CPS                         4            
   PS                               2            
  AEDs before operation                          N/A
   VPA                              9            
   CMZ                              6            
   TPM                              3            
   PB                               2            
   OMZ                              2            
   LEV                              5            
   LTG                              2            
   PHT                              1            
   CZP                              1            

GS: generalized seizure; GTCS: generalized tonic clonic seizure; CPS: complex partial seizure; PS: partial seizure; VPA: valproic acid; CMZ: carbamazipine; TPM: topiramate; PB: phenobarbital; OMZ: oxcarbazepine; LEV: levetiracetam; LTG: lamotrigine; PHT: phenytoin; CZP: clonazepam; N/A: non applicable.

No significant difference in distribution of DNA methylation reads {#s2_2}
------------------------------------------------------------------

In each sample, 81632654 methylation reads (49 bp) were sequenced. In epileptic samples, an average 71.20% of the reads were uniquely mapped to the reference genome, and in controls, 70.77% of the reads were uniquely mapped. There was no significant difference of uniquely mapped reads between the two groups by T test ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}).

Moreover, no significant difference was identified between epileptic samples and controls in 1) genome coverage distribution across sequencing depth, 2) distribution of CpG, CHG, and CHH sites across sequencing depth, 3) reads distribution in genome regions with different CpG density, 4) distribution of reads in different gene elements and repetitive elements, 5) distribution of reads around CpG island and gene body.

No significant difference in distribution of DNA methylation peaks {#s2_3}
------------------------------------------------------------------

In each epileptic sample, an average of 115128.10±21674.80 peaks were identified, covering an average of 152796189.80±26659961.36 bp and 4.87±0.85% of human genome. In controls, the mean identified peaks were 111020.20±25956.50, covering 148106055.60±25489074.79 bp and 4.72±0.81% of human genome ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}). No significant difference between the two groups was found. In addition, no significant difference in the number of peaks with different length, the distribution of peaks with different CpG density and distribution of peaks in gene elements (including peak number and peak coverage) was observed between epileptic samples and control.

Analysis of differentially methylated regions (DMR) and DMGs {#s2_4}
------------------------------------------------------------

The median of DMRs identified by pairwise comparison was 7604.50, covering a median of 8580791.00 bp. The distribution of DMGs in paired samples was mapped to human genome using Circos \[[@R20]\] (Figure [1](#F1){ref-type="fig"}). DMGs appeared on all of chromosomes extensively except for Y chromosome in refractory epilepsy patients.

![Distribution of differentially methylated genes (DMGs) across genome\
Hyper-methylated (purple) and hypo-methylated (green) regions in epileptic samples vs. controls were targeted to each chromosome. Diverse distribution of DMGs was found in X chromosome, while DMGs appeared rarely in Y chromosome.](oncotarget-07-87402-g001){#F1}

The significant enriched gene ontology (GO) terms of DMGs were presented in Table [2](#T2){ref-type="table"}. Most of the DMGs were differentially methylated in gene element of CDS and introns. Significant enrichment of DMGs was observed in GO terms of binding of various molecules, such as ATP binding, ion binding, cation binding, and nucleoside binding. In addition, DMG enrichment was also identified in the GO terms involved in receptor activity, transporter activity, kinase activity, transducer activity and channel activity. Those DMGs participate mainly in the biological processes of adhesion and ion transport.

###### GO enrichment analysis of differentially methylated genes

  Element    Category   Terms
  ---------- ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CDS        C          apical part of cell; apical plasma membrane; axonemal dynein complex; basement membrane; cell surface; cytoplasm; cytoskeleton; cytoskeleton; dynein complex; extracellular matrix; extracellular matrix part;extracellular region; extracellular region part; extracellular space; insoluble fraction; integral to plasma membrane; intracellular; intracellular organelle; intracellular organelle part;intracellular part; intrinsic to plasma membrane; membrane; membrane attack complex; membrane fraction; membrane part; membrane-bounded organelle; myosin complex; myosin filament;nucleolus; organelle; organelle part; plasma membrane; plasma membrane part; platelet alpha granule lumen; proteinaceous extracellular matrix; striated muscle thick filament
             F          GTPase binding; adenyl nucleotide binding; adenyl ribonucleotide binding; ATP binding; calcium ion binding;calmodulin binding; collagen binding; extracellular matrix structural constituent; GTPase regulator activity; guanyl-nucleotide exchange factor activity; microtubule motor activity;motor activity; NAD(P)H oxidase activity; nucleoside binding; phosphotransferase activity, alcohol group as acceptor; purine nucleoside binding; purine nucleotide binding;Ras guanyl-nucleotide exchange factor activity; Rho guanyl-nucleotide exchange factor activity; small GTPase binding
             P          cell adhesion; biological adhesion
  Intron     C          synapse; actin cytoskeleton; basement membrane; basolateral plasma membrane; cell; cell junction; cell part;cell projection; cytoskeleton; extracellular matrix; extracellular region part; integral to membrane;integral to plasma membrane; intrinsic to membrane; intrinsic to plasma membrane;membrane; membrane part; neuron projection; plasma membrane; plasma membrane part;postsynaptic membrane; presynaptic membrane; proteinaceous extracellular matrix; synapse part
             F          actin binding; adenyl nucleotide binding; adenyl ribonucleotide binding; ATP binding; binding; cadherin binding;calcium channel activity; calcium ion binding; cation binding; cation channel activity; cell adhesion molecule binding; channel activity; cytoskeletal protein binding; diacylglycerol binding;extracellular-glutamate-gated ion channel activity; gated channel activity; glutamate receptor activity; GTPase regulator activity; guanyl-nucleotide exchange factor activity;ion binding; ion channel activity; ion transmembrane transporter activity;ionotropic glutamate receptor activity; kinase activity; ligand-gated channel activity;ligand-gated ion channel activity; metal ion binding; metal ion transmembrane transporter activity;molecular transducer activity; nucleoside binding; nucleoside-triphosphatase regulator activity;passive transmembrane transporter activity; phosphoric diester hydrolase activity;phosphotransferase activity, alcohol group as acceptor; protein kinase activity;protein tyrosine kinase activity; protein tyrosine phosphatase activity; purine nucleoside binding;Rho GTPase activator activity; signal transducer activity; transferase activity, transferring phosphorus-containing groups; transmembrane receptor protein kinase activity;transmembrane receptor protein tyrosine kinase activity
             P          cell adhesion; biological adhesion; homophilic cell adhesion; cell-cell adhesion; ion transport; metal ion transport
  5'-UTR     C          membrane attack complex
             F          calcium-dependent protein binding
             P          none
  3'-UTR     C          glycerol-3-phosphate dehydrogenase complex
             F & P      none
  Promoter   C          synaptosome
             F          transmembrane receptor activity; receptor activity; G-protein coupled receptor activity; signal transducer activity;molecular transducer activity; olfactory; voltage-gated ion channel activity; voltage-gated channel activity
             P          G-protein coupled receptor protein signaling pathway; cell surface receptor linked signal transduction;sensory perception of chemical stimulus; inorganic; anion transport

Gene expression profiling {#s2_5}
-------------------------

In each epileptic sample, an average of 78044550.80±8806016.67 reads covering 7024009572.00±792541500.40 bp were sequenced, among which an average 83.71% of reads were uniquely mapped to reference genome, and 66.95% of reads were uniquely mapped to reference genes. In controls, an average of 79185195.80±9170582.72 reads covering 7126667622.00±825352445.10 bp were sequenced, among which an average 83.80% of reads were uniquely mapped to reference genome, and 65.99% of reads were uniquely mapped to reference genes. No significant difference was found between the two groups by T test (p\<0.05 was considered statistically significant). ([Supplementary Table S3](#SD1){ref-type="supplementary-material"}).

A total of 21353 genes were sequenced, among which 17665 genes were expressed by all samples. The sequencing coverage of 65.01% and 65.45% genes was over 90% in epileptic samples and controls, respectively, indicating a good sequencing quality.

Pairwise comparison identified 8850 differentially expressed genes (DEG), among which 885 genes were differentially expressed in ≥5 of the 10 pairs (Figure [2](#F2){ref-type="fig"}). Out of the 8850 DEGs, 246 were epilepsy-related genes according to NCBI Gene (<http://www.ncbi.nlm.nih.gov/gene>), and 34 epilepsy-related genes were differentially expressed in ≥5 of the 10 pairs (Table [3](#T3){ref-type="table"}). However, only 3 out of the 65 genes differentially expressed in ≥8 pairs of the 10 pairs were epilepsy-related genes according to NCBI Gene (Table [4](#T4){ref-type="table"}), which suggested that some new DEGs, including AZGP1, MMP19, DES, LGR6, SERPINA3, CX3CR1, DUSP5, EGR4, GPR37, etc. might be correlated with refractory epilepsy.

![The gene expression signature of differentially expressed genes in ≥ 5 pairs of samples\
(purple: expression up; green: expression down; black: no difference). The hierarchical cluster showed a distinct expression signature with viariation between the paired samples.](oncotarget-07-87402-g002){#F2}

###### Differentially expressed epilepsy-relate genes in ≥ 5 pairs of samples

  Symbol     description                                                             Epilepsy-Related Disorders
  ---------- ----------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  AQP1       aquaporin 1                                                             refractory epilepsy/mesial temporal lobe sclerosis
  ATF3       activating transcription factor 3                                       refractory mTLE
  C3         complement component 3                                                  TLE/FS/seizures following acute viral infection
  CALB2      calbindin 2                                                             TLE/FCD/LTP
  CCR5       chemokine (C-C motif) receptor 5                                        refractory epilepsy/infantile-onset epilepsy/SUDEP/SE
  EGR1       early growth response 1                                                 IAE/focal epilepsy
  EMP1       epithelial membrane protein 1                                           refractory epilepsy
  GRIN2B     glutamate receptor, ionotropic, N-methyl D-aspartate 2B                 West syndrome/FCD/TLE/anti-NMDAR encephalitis
  HLA-DQA1   major histocompatibility complex, class II, DQ alpha 1                  IGE/JME/absence epilepsy
  HP         haptoglobin                                                             IGE/familial epilepsy
  IL1A       interleukin 1, alpha                                                    TLE/FS
  IL1B       interleukin 1, beta                                                     epilepsy
  IL1RN      interleukin 1 receptor antagonist                                       TLE
  IL6        interleukin 6                                                           TLE/FS/familial epilepsy/refractory epilepsy
  CXCL8      chemokine (C-X-C motif) ligand 8                                        refractory epilepsy
  IL18       interleukin 18                                                          seizures in MS
  ITGA2      integrin, alpha 2                                                       refractory epilepsy
  KCNA1      potassium channel, voltage gated shaker related subfamily A, member 1   SUDEP/TLE/partial epilepsy/Myokymia
  NPY        neuropeptide Y                                                          absence epilepsy/TLE/SE
  OPRM1      opioid receptor, mu 1                                                   tonic-clonic seizures/TLE/IGE/SE/IAE
  PDYN       prodynorphin                                                            TLE/FLTLE
  RELN       reelin                                                                  TLE
  PTGS2      prostaglandin-endoperoxide synthase 2                                   mTLE/absence seizures/poststroke seizures
  SCN1B      sodium channel, voltage gated, type I beta subunit                      Genetic GEFS+/Dravet Syndrome/convulsions with gastroenteritis/BPEI/LQTS/brugada syndrome
  SCN5A      sodium channel, voltage gated, type V alpha subunit                     Dravet syndrome/SUDEP/BFNS/LQTS/brugada syndrome
  CCL2       chemokine (C-C motif) ligand 2                                          refractory epilepsy/SE
  CCL4       chemokine (C-C motif) ligand 4                                          TLE
  CDKL5      cyclin-dependent kinase-like 5                                          West syndrome/early-onset epileptic encephalopathies
  CNTN2      contactin 2 (axonal)                                                    PME/Autosomal recessive epilepsy/Autoimmune epilepsy
  TNF        tumor necrosis factor                                                   TLE/refractory epilepsy
  TRPC4      transient receptor potential cation channel, subfamily C, member 4      generalized epilepsy with photosensitivity
  CACNA1H    calcium channel, voltage-dependent, T type, alpha 1H subunit            IGE/CAE/generalized epilepsy syndromes
  PLCB1      phospholipase C, beta 1 (phosphoinositide-specific)                     early infantile epilepsy syndromes/malignant migrating partial seizures in infancy
  ERMN       ermin, ERM-like protein                                                 epileptic seizure/oligodendrocytes and epilepsy

mTLE: mesial temporal lobe epilepsy; TLE: temporal lobe epilepsy; FS: febrile seizures; FCD: focal cortical dysplasia; LTP: long-term potentiation; SUDEP: sudden unexpected death in epilepsy; SE: status epilepticus; IAE: idiopathic absence epilepsy; IGE: idiopathic generalized epilepsy; JME: juvenile myoclonic epilepsy; MS: multiple sclerosis; FLTLE: familial lateral temporal lobe epilepsy; GEFS+: generalized epilepsy with febrile seizure plus; BPEI: benign partial epilepsy in infancy; LQTS: long QT syndrome; BFNS: benign familial neonatal seizure; PME: progressive myoclonic epilepsy; CAE: childhood absence epilepsy.

###### Differentially expressed genes in ≥8 pairs of the samples

  Symbol      Description                                                                           Symbol          Description
  ----------- ------------------------------------------------------------------------------------- --------------- ---------------------------------------------------------------------------------------
  SERPINA3    serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3   SOCS3           suppressor of cytokine signaling 3
  AQP1^a^     aquaporin 1 (Colton blood group)                                                      CH25H           cholesterol 25-hydroxylase
  AZGP1       alpha-2-glycoprotein 1, zinc-binding                                                  CD163           CD163 molecule
  BMP5        bone morphogenetic protein 5                                                          CARTPT          CART prepropeptide
  CHRM5       cholinergic receptor, muscarinic 5                                                    KCNH4           potassium channel, voltage gated eag related subfamily H, member 4
  CX3CR1      chemokine (C-X3-C motif) receptor 1                                                   CDH19           cadherin 19, type 2
  DES         desmin                                                                                BLNK            B-cell linker
  DUSP5       dual specificity phosphatase 5                                                        GCNT4           glucosaminyl (N-acetyl) transferase 4, core 2
  EGR4        early growth response 4                                                               TNFRSF12A       tumor necrosis factor receptor superfamily, member 12A
  FCGR3A      Fc fragment of IgG, low affinity IIIa, receptor (CD16a)                               CD244           CD244 molecule, natural killer cell receptor 2B4
  FOS         FBJ murine osteosarcoma viral oncogene homolog                                        LGR6            leucine-rich repeat containing G protein-coupled receptor 6
  FOSB        FBJ murine osteosarcoma viral oncogene homolog B                                      STRA6           stimulated by retinoic acid 6
  GPR37       G protein-coupled receptor 37 (endothelin receptor type B-like)                       SH3TC2          SH3 domain and tetratricopeptide repeats 2
  GRIN2B^a^   glutamate receptor, ionotropic, N-methyl D-aspartate 2B                               DCSTAMP         dendrocyte expressed seven transmembrane protein
  HBA2        hemoglobin, alpha 2                                                                   CNDP1           carnosine dipeptidase 1 (metallopeptidase M20 family)
  HBB         hemoglobin, beta                                                                      PNMA6A          paraneoplastic Ma antigen family member 6A
  SERPIND1    serpin peptidase inhibitor, clade D (heparin cofactor), member 1                      SLC5A11         solute carrier family 5 (sodium/inositol cotransporter), member 11
  HDC         histidine decarboxylase                                                               KIF19           kinesin family member 19
  HLA-DRB5    major histocompatibility complex, class II, DR beta 5                                 FREM3           FRAS1 related extracellular matrix 3
  HSD11B1     hydroxysteroid (11-beta) dehydrogenase 1                                              DLGAP1-AS3      DLGAP1 antisense RNA 3
  HTR3A       5-hydroxytryptamine (serotonin) receptor 3A, ionotropic                               C20orf166-AS1   C20orf166 antisense RNA 1
  TNC         tenascin C                                                                            NPAS4           neuronal PAS domain protein 4
  IL6^a^      interleukin 6                                                                         HMGA1P7         high mobility group AT-hook 1 pseudogene 7
  ITK         IL2-inducible T-cell kinase                                                           C11orf96        chromosome 11 open reading frame 96
  LRP2        low density lipoprotein receptor-related protein 2                                    TMEM233         transmembrane protein 233
  MBP         myelin basic protein                                                                  TMEM215         transmembrane protein 215
  MC4R        melanocortin 4 receptor                                                               CTXN3           cortexin 3
  MMP19       matrix metallopeptidase 19                                                            LOC643711       platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (30kDa) pseudogene
  NPPA        natriuretic peptide A                                                                 LOC100130331    POTE ankyrin domain family, member F pseudogene
  VCAM1       vascular cell adhesion molecule 1                                                     CD24            CD24 molecule
  ZFP36       ZFP36 ring finger protein                                                             BRE-AS1         BRE antisense RNA 1
  NR4A3       nuclear receptor subfamily 4, group A, member 3                                       LINC00507       long intergenic non-protein coding RNA 507
  BAIAP3      BAI1-associated protein 3                                                                             

a: Epilepsy-related genes according to NCBI Gene (<http://www.ncbi.nlm.nih.gov/gene>).

Pairwise comparison presented a total of 395 GO terms significantly enriched in epileptic samples compared to controls (Component 68, Function 70, Process 257). 77 GO terms were significantly enriched in ≥5 epileptic samples compared to controls, including 12 component terms, 23 function terms and 42 process terms (Table [5](#T5){ref-type="table"}). The GO enrichment analysis of gene expression revealed that the biological functions of DEGs are mainly correlated with channel activity, transporter activity, and receptor activity. Furthermore, the biological processes mainly targeted by DEGs were immune system, biological regulation, response to stimulus, signaling, development, and behavior.

###### Enriched GO terms and KEGG pathways in epileptic sample

  Term                                                               Genes   Term                                                              Genes
  ------------------------------------------------------------------ ------- ----------------------------------------------------------------- -------
  GO Component                                                                                                                                 
  GO:0071944-Cell periphery                                          516     GO:0016020-Membrane                                               2319
  GO:0009986-Cell surface                                            48      GO:0044425-Membrane part                                          1912
  GO:0005576-Extracellular region                                    333     GO:0016021-Integral to membrane                                   509
  GO:0044421-Extracellular region part                               326     GO:0031224-Intrinsic to membrane                                  1654
  GO:0031012-Extracellular matrix                                    114     GO:0005886-Plasma membrane                                        511
  GO:0005578-Protenaceous extracellular matrix                       44      GO:0044459-Plasma membrane part                                   488
  GO Function                                                                                                                                  
  GO:0015267-Channel activity                                        172     GO:0001653-Peptide receptor activity                              39
  GO:0005261-Cation channel activity                                 113     GO:0008528-Peptide receptor activity, G-protein coupled           36
  GO:0005216-Ion channel activity                                    167     GO:0060089-Molecular transducer activity                          586
  GO:0022838-Substrate-specific channel activity                     167     GO:0004871-Signal transducer activity                             506
  GO:0005215-Transporter activity                                    402     GO:0005515-Protein binding                                        1337
  GO:0022857-Transmembrane transporter activity                      241     GO:0005102-Receptor binding                                       286
  GO:0015075-Ion transmembrane transporter activity                  276     GO:0001871-Pattern binding                                        59
  GO:0022803-Passive transmembrane transporter activity              173     GO:0042277-Peptide binding                                        50
  GO:0022892-Substrate-specific transporter activity                 367     GO:0030246-Carbohydrate binding                                   120
  GO:0022891-Substrate-specific transmembrane transporter activity   220     GO:0030247-Polysaccharide binding                                 57
  GO:0004872-Receptor activity                                       347     GO:0005539-Glycosaminoglycan binding                              52
  GO:0004888-Transmembrane receptor activity                         225                                                                       
  GO Process                                                                                                                                   
  GO:0001775-Cell activation                                         421     GO:0009605-Response to external stimulus                          42
  GO:0007154-Cell communication                                      120     GO:0009617-Response to bacterium                                  201
  GO:0030154-Cell differentiation                                    1390    GO:0009991-Response to extracellular stimulus                     287
  GO:0002376-Immune system process                                   449     GO:0031667-Response to nutrient levels                            79
  GO:0032501-Multicellular organismal process                        604     GO:0009611-Response to wounding                                   168
  GO:0032501-Biological regulation                                   160     GO:0023052-Signaling                                              75
  GO:0050789-Regulation of biological process                        1153    GO:0019932-Second-messenger-mediated signaling                    308
  GO:0048518-Positive regulation of biological process               146     GO:0023033-Signaling pathway                                      96
  GO:0065008-Regulation of biological quality                        326     GO:0007166-Cell surface receptor linked signaling pathway         1022
  GO:0050793-Regulation of developmental process                     283     GO:0007186-G-protein coupled receptor protein signaling pathway   434
  GO:0002682-Regulation of immune system process                     898     GO:0009653-Anatomical structrue morphogenesis                     67
  GO:0051239-Regulation of multicellular organismal process          1211    GO:0048856-Anatomical structure development                       89
  GO:0050896-Response to stimulus                                    496     GO:0007275-Multicellular organismal development                   239
  GO:0042221-Response to chemical stimulus                           527     GO:0032502-Developmental process                                  614
  GO:0010033-Response to organic substance                           1625    GO:0048869-Cellular developmental process                         332
  GO:0006950-Response to stress                                      669     GO:0048731-System development                                     1342
  GO:0006952-Defense response                                        259     GO:0048513-Organ development                                      906
  GO:0009719-Response to endogenous stimulus                         201     GO:0009888-Tissue development                                     824
  GO:0009725-Response to hormone stimulus                            350     GO:0007610-Behavior                                               988
  GO:0048545-Response to steroid hormone stimulus                    59      GO:0006811-Ion transport                                          222
  GO:0031960-Response to corticosteroid stimulus                     615     GO:0048878-Chemical homeostasis                                   182
  KEGG Pathway                                                                                                                                 
  ko05143-African trypanosomiasis                                    36      ko04640-Hematopoietic cell lineage                                110
  ko05330-Allograft rejection                                        38      ko04672-Intestinal immune network for IgA production              37
  ko05146-Amoebiasis                                                 120     ko05140-Leishmaniasis                                             87
  ko05310-Asthma                                                     24      ko04670-Leukocyte transendothelial migration                      151
  ko05320-Autoimmune thyroid disease                                 43      ko05144-Malaria                                                   47
  ko04662-B cell receptor signaling pathway                          92      ko04650-Natural killer cell mediated cytotoxicity                 109
  ko04020-Calcium signaling pathway                                  177     ko04080-Neuroactive ligand-receptor interaction                   244
  ko04514-Cell adhesion molecules                                    137     ko04380-Osteoclast differentiation                                127
  ko04062-Chemokine signaling pathway                                151     ko04145-Phagosome                                                 197
  ko04610-Complement and coagulation cascades                        113     ko05020-Prion diseases                                            54
  ko04060-Cytokine-cytokine receptor interaction                     171     ko05323-Rheumatoid arthritis                                      78
  ko04512-ECM-receptor interaction                                   155     ko05150-Staphylococcus aureus infection                           85
  ko04666-Fc gamma R-mediated phagocytosis                           116     ko04940-Type I diabetes mellitus                                  45
  ko05332-Graft-versus-host disease                                  43                                                                        

In Kyoto Encyclopedia of Genes and Genome (KEGG) pathway enrichment analysis, 75 pathways were significantly enriched in epileptic samples compared to controls, while 27 pathways were significantly enriched in ≥5 epileptic samples compared to controls (Table [5](#T5){ref-type="table"}). DEGs mainly participate in calcium signaling pathway, neuroactive ligand-receptor interaction, and pathways involved in inflammation, immune response, and autoimmune diseases.

DNA methylation and gene expression {#s2_6}
-----------------------------------

The distribution of hyper-, hypo- and unmethylated gene expression levels in different gene elements were presented in Figure [3](#F3){ref-type="fig"}. The trend of gene expression of the three groups were similar, and in all the 5 elements, the percentage of hyper-methylated genes with log~2~(RPKM ratio) (RPKM ratio = RPKM of epileptic sample/RPKM of control) approximately ranging from 1 to 3 were higher than that of hypo-methylated and unmethylated genes. Generally, no significant relationship in modulation was found between DNA methylation and gene expression.

![The distribution of hyper-, hypo- and unmethylated gene expression levels in different gene elements\
No significant relationship was found between DNA methylation and gene expression in all the 5 gene elements, and the percentage of hyper-methylated genes with log2(RPKM ratio) approximately ranging from 1 to 3 were higher than that of hypo-methylated and unmethylated genes.](oncotarget-07-87402-g003){#F3}

DISCUSSION {#s3}
==========

It is the first genome-wide report on DNA methylation and gene expression in refractory epilepsy patients. 62 differentially expressed genes such as MMP19, AZGP1, DES, and LGR6 were discovered to be correlated with refractory epilepsy, and diverse distribution of differentially methylated genes was found in X chromosome instead of in Y chromosome.

Although many genes were observed differentially methylated or expressed, the general distribution of DNA methylation reads, DNA methylation peaks and mRNA sequencing reads were similar between refractory epileptic samples and controls, which indicate no significant difference in global DNA methylation and global gene expression between the two groups. Inconsistent with previous report which identified decreased DNA methylation in Y chromosome of TLE patients \[[@R18]\], our study presented no difference in DNA methylation in Y chromosome between refractory epileptic samples and controls. It is noteworthy that 4 out of the 5 male epileptic samples in our study were frontal lobe epilepsy, suggesting a possible difference in DNA methylation in Y chromosome between frontal lobe epilepsy and TLE. On the contrary to a previous research which found no change of DNA methylation in X chromosome in rat models of epilepsy \[[@R17]\], we identified diverse DMR distribution on X chromosome in all patients. This difference may be attributed to the much more complicated environmental factors involved by human beings or the difference between species.

In pairwise comparison of gene expression analysis, we identified distinct gene expression signatures. 34 DEGs are correlated with epilepsy or seizure and 14 of these genes are associated with refractory epilepsy, such as AQP1 \[[@R21]\], CCR5 \[[@R22]\], EMP1 \[[@R23]\], CXCL8 \[[@R24]\], ITGA2 \[[@R25]\], and CCL2 \[[@R26]\]. For the first time, 62 DEGs differentially expressed in ≥8 pairs of samples were found related to epilepsy/seizure in our study. These newly-identified refractory epilepsy-related genes may possibly reveal new mechanisms of refractory epilepsy. In all the DEGs, only MMP19 and AZGP1 were differentially expressed in all the 10 pairs. Compared to the controls, 9 of the 10 epileptic samples showed increased expression of MMP19, while 1 epileptic sample showed decreased expression. MMP19 and other matrix metalloproteinases can cleave and remodel the extracellular matrix, including tenascin and laminin, and thus influence synapse formation and remodeling, N-methyl-D-aspartate receptor activity, learning and memory, and hippocampal long-term potentiation \[[@R27]\]. Inhibition of MMP19 and other matrix metalloproteinases may prevent development of epilepsy at the early stage of epileptogenesis \[[@R28]\]. Meanwhile, we found the expression of AZGP1 were decreased in 8 of the 10 epileptic samples, and increased in 2 of the 10 epileptic samples when compared to controls. AZGP1 encodes Zinc-a2-glycoprotein, which is an adipokine participates in lipid mobilization, lipolytic effect, and immune response \[[@R29], [@R30]\]. Moreover, both DES in 9 pairs and LGR6 in 8 pairs showed consistently increased expression in epileptic samples. To the best of our knowledge, it is the first time that MMP19, AZGP1, DES, and LGR6 were reported to be correlated with refractory epilepsy.

Significant enrichment of DMGs in GO terms of binding, transport, and enzymatic activity were found, which is consistent with previous studies \[[@R18]\]. Interestingly, most of the DMGs were differentially methylated in CDS and intron, while previous research showed differential methylation in all the gene elements in rat models of chronic epilepsy induced by pilocarpine \[[@R17]\]. These findings indicate DNA methylation in CDS and intron may play critical roles in refractory epilepsy besides promoter methylation which has been a very popular target in research on epilepsy \[[@R18], [@R31]\]. The GO enrichment analysis of gene expression revealed a trend similar to a previous report \[[@R17]\] that the DEGs are mainly correlated with biological functions such as protein binding, receptor binding, channel activity, transporter activity, and receptor activity, as well as being involved in biological processes such as immune system, biological regulation, response to stimulus, signaling, development, and behavior.

The change of DNA methylation in this study is not exactly corresponded with alteration of gene expression. Kobow and his colleagues found that DNA methylation in promoter, exon and intron were inversely correlated with gene expression in rat models of chronic epilepsy induced by pilocarpine \[[@R17]\], but our study found that most of the hyper- and hypo-methylated genes were not differentially expressed in epilepsy patients, and the percentage of hyper-methylated genes with log2(RPKM ratio) ranging from 1 to 3 were higher than that of hypo-methylated and unmethylated genes, which indicate a complicated modulation between DNA methylation and gene expression in refractory epilepsy in human beings.

In KEGG analysis of gene expression, DEGs significantly enriched in calcium signaling pathway, neuroactive ligand-receptor interaction, and pathways participating in inflammation, immune response, autoimmune diseases. Calcium signaling pathway has been increasingly recognized as a vital factor in epileptogenesis and the excess synchronization, and hyperexcitability of neurons for seizures can be linked to various calcium signaling pathways \[[@R32]\]. The aberrantly neuroactive ligand-receptor interaction can enhance the susceptibility to epileptic seizures \[[@R33], [@R34]\]. It may explain partially that the drugs regulating the function of calcium signaling pathway and neuroactive ligand-receptor interaction are able to alleviate the seizure frequency \[[@R35]\]. The roles of immune response and inflammation in epilepsy have been recognized in previous studies \[[@R36]\]. Autoimmune epilepsy frequently present drug-resistance which can be controlled by immunosuppressive and immunomodulatory therapies \[[@R36], [@R37]\]. Consistent with Lukic and his colleagues' study, we also identified that prion disease was significantly targeted by DEGs which indicate both refractory epilepsy and prion diseases may share some common pathway \[[@R38]\].

MATERIALS AND METHODS {#s4}
=====================

Study approval {#s4_1}
--------------

The research protocol was approved by the Ethics Committees of the Second Affiliated Hospital of Chongqing Medical University. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration. Written informed consent was obtained from all individual participants included in the study or their proxies.

Patients and tissues preparation {#s4_2}
--------------------------------

Resected brain tissues were retrospectively but consecutively collected from 10 patients with refractory epilepsy and 10 patients with post-traumatic intracranial hypertension who underwent surgical treatment since 2008 to 2014. Patients with refractory epilepsy were diagnosed following the definition of ILAE \[[@R39]\]. Briefly, all patients were resistant to maximum doses of at least three anti-epileptic drugs (AED), and evaluated by detailed history, neurological examination, neuropsychological test and neuroimaging data. For presurgical evaluation and epileptogenic zones identification, a combined assessment of ictal simiology, brain magnetic resonance imaging, video-electroencephalography, sphenoidal electrode monitoring and intracerebral electroencephalography and intraoperative electrocorticography were applied. After evaluation, standard en bloc resection was performed. No refractory epilepsy patient received adjustment of AEDs during the 2 months before surgery. Brain tissues as control from the 10 post-trauma intracranial hypertension patients were identified normal by neuropathologist. These patients had no history of epilepsy or exposure to AEDs. All the resected brain tissues were immediately frozen in liquid nitrogen and then stored at -80°C.

The 10 epileptic samples and 10 controls were paired, the difference in genome-wide DNA methylation and gene expression between the paired samples were analyzed using MeDIP-seq and mRNA-seq.

DNA methylation profiling {#s4_3}
-------------------------

Genomic DNA was extracted using QIAamp DNA Micro Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instruction. Extracted DNA was fragmented to a size of 100-500 bp by sonication (Bioruptor NGS, Digenode, Liege, Belgium), and subjected to DNA-end repair, 3'-dA overhang and ligation of sequencing adaptors according to manufacturer\'s instruction (Paired-End DNA Sample Prep kit, Illumina, San Diego, USA) and denatured to single-stranded. Then the methylated DNA was immunoprecipitated by 5mc antibody (Magnetic Methylated DNA Immunoprecipitation kit, Diagenod, Liege, Belgium). After Real-time Quantitative polymerase chain reaction (PCR) (TaqMan Probe, Applied Biosystems, Thermo Fisher Scientific, Waltham, USA) validation and quality control of sample library (Agilent 2100 BioAnalyzer, Agilent, Santa Clara, USA), electrophoretically selected DNA fragments sizing from 200-300 bp were subjected to high-throughput sequencing (Illumina HiSeqTM 2000, Illumina, San Diego, USA). Sequencing strategy was Single-end 50 bp, and reads size was 49 bp.

Filtered MeDIP-Seq data (Adapters, reads containing more than 10% bases undetermined, and low quality reads were removed. Low quality read means the quality values (Q) of more than 50% bases in this read were ≤20, Q=-10lg(rate of sequencing error)) was mapped to reference genome using SOAP software, version 2.21 (Website: <http://soap.genomics.org.cn>)\[[@R40]\], only unique alignments with no more than 2 mismatches were included for further analysis. The reference genome data and the data used for annotation of all aligned genes were from UCSC Genome Bioinformatics Download (Reference genome: <http://hgdownload.cse.ucsc.edu/goldenPath/hg19/chromosomes/chr>\*.fa.gz. Reference genes: <http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/chromOut.tar.gz>).

To describe the distribution of MeDIP-Seq data on genome, the following items were calculated: 1) Genome coverage distribution across sequencing depth; 2) Distribution of CpG, CHG and CHH sites varies with sequencing depth; 3) Reads distribution in genome regions with different CpG density; 4) Distribution of reads in different gene elements, including CpG islands, promoters, 5'-Untranslated regions (UTR), CDS, introns, 3'-UTR, repeat regions and each class of repetitive elements (Repeat dataset is obtained from RepeatMasker (Transposons) and Tandem Repeats Finder (Tandom repeats), and is available at:<http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/chromOut.tar.gz>); 5) Distribution of MeDIP-Seq reads around CpG island and gene body.

Whole genome scanning of enrichment region of methylation/Peak was based on a defined analysis model, MACS 1.4.0 (Website:<http://liulab.dfci.harvard.edu/MACS/>) with default parameters \[[@R41]\]. The following items were calculated: 1) Distribution of peaks with different length; 2) Distribution of peaks with different CpG density; 3) Number and coverage of peaks in gene elements (promoter, 5'-UTR, CDS, intron, and 3'-UTR).

DMGs based on peak of all the paired samples were analyzed. Briefly, peaks of the paired two samples were merged as candidate DMRs. For each candidate DMR, the number of reads of each sample was calculated and tested to get true DMRs. The downtrend DMRs indicate that the number of reads of the control sample was larger than the epileptic sample and the uptrend DMRs indicate the opposite. DMGs were defined as the genes overlapping DMRs. Genes with an element merely overlap uptrend DMRs were considered hyper-methylated with such an element, genes with an element merely overlap downtrend DMRs were considered hypo-methylated with such an element.

To clarify the biological functions of DMGs, GO enrichment analysis was performed. Briefly, DMGs were mapped to GO terms in reference database (<http://www.geneontology.org>) and gene numbers for every term were calculated and tested to identify the significantly enriched GO terms.

Gene expression profiling {#s4_4}
-------------------------

RNA was extracted using Trizol method. After DNase I treatment, mRNA was isolated with magnetic beads with Oligo (dT) and fragmented. Then cDNA was synthesized using the mRNA fragments as templates. The synthesized cDNA fragments were purified and subjected to end reparation, single nucleotide adenine addition and adapter connection. cDNA fragments suitable for PCR amplification were selected with electrophoresis. Quality control of sample library was performed using Agilent 2100 Bioanaylzer (Agilent, Santa Clara, USA) and Applied Biosystems StepOnePlus Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific, Waltham, USA). The library was sequenced using Illumina HiSeqTM 2000 (Illumina, San Diego, USA).

After sequencing quality control, the mRNA-Seq data was mapped to reference genome and reference genes using SOAP software, version 2.21 (Website:<http://soap.genomics.org.cn>) \[[@R40]\]. Then the distribution of reads on reference genome and genes was calculated and coverage analysis was performed. After alignment quality control, the DEGs were selected. And for further analysis, expression pattern analysis of DEGs were also performed.

To clarify the biological functions of DEGs, GO enrichment analysis of DEGs was performed as described above. To further clarify the biological functions of DEGs, KEGG pathway analysis was performed using the same calculating formula as GO enrichment analysis with database available at http://www.kegg.jp/kegg/.

Correlation analysis of DNA methylation and gene expression {#s4_5}
-----------------------------------------------------------

The distribution of hyper-, hypo- and unmethylated gene expression levels in different gene elements were calculated to analyze the relationship between DNA methylation and gene expression as previously described \[[@R42]\].

Statistics and analysis {#s4_6}
-----------------------

To identify true DMRs, the numbers of reads were calculated and assessed using chi-square statistics and False discovery rate (FDR) statistics (p≤0.01, and the difference of read numbers should be more than twice). To identify significantly enriched GO terms and KEGG pathways, gene numbers for every term or pathway were calculated and then assessed using hypergeometric test, p-value of hypergeometric test was corrected using Bonferroni Correction \[[@R43]\]. GO terms with corrected p-value ≤0.01, and KEGG pathways with corrected p-value ≤0.05 were considered significantly enriched. In selection of DEGs, the gene expression level was calculated using RPKM method \[[@R44]\], and DEGs were selected as previously described \[[@R45]\]. The adjusted p-value was calculated using Benjamini, Yekutieli. 2001 FDR method \[[@R46]\] and DEGs was defined as genes with FDR≤0.001 and the RPKM difference between the paired samples should be more than twice. Hierarchical cluster was performed to analyze the expression pattern of DEGs using Cluster \[[@R47]\] and presented using Java Treeview \[[@R48]\]. The DEGs were clustered by Euclidean distance.

Abbreviations {#s4_7}
-------------

CDS=coding sequences; DMG=differentially methylated genes; DMR=Differentially Methylated Regions; DEG=differentially expressed genes; GO=gene ontology; ILAE=International League Against Epilepsy; KEGG=Kyoto Encyclopedia of Genes and Genome; MeDIP-Seq=methylated DNA immunoprecipitation linked with sequencing; mRNA-Seq=mRNA sequencing; PCR=polymerase chain reaction; RPKM=Reads Per Kilobases per Millionreads; TLE=temporal lobe epilepsy; UTR=Untranslated regions.
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